Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02583568

Fluorescence Guided Surgery in Breast Cancer (MARGIN)

Phase II, Open-Label Study to Evaluate Safety and Explore Efficacy of Escalating Doses of Bevacizumab-IRDye800CW as an Optical Imaging Agent to Detect Cancer Tissue Delineation During Tumor Resection Surgery in Patients With Breast Cancer

Sponsor: Martini Hospital Groningen

Conditions Breast Cancer

Interventions Bevacizumab-800CW

Updated 6 times since 2017 Last updated: Feb 10, 2017 Started: Oct 31, 2015 Primary completion: Jan 31, 2017 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Martini Hospital Groningen and has accumulated 6 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Martini Hospital Groningen
University Medical Center Groningen

Data source: University Medical Center Groningen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands